The company states: “On April 21, after a decades-long career, Melissa Baird, Chief Operating Officer of Hims & Hers Health, announced her intention to transition into an advisory role with Hims ...

Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven ...

Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) issued a warning about topical finasteride, a hair-loss treatment sold ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide ...

But one standout stock has nearly doubled the market - over the past five years, Hims & Hers Health has surged 172% to $26.89 per share. Its momentum hasn’t stopped as it’s also gained 25.8% ...

Throughout the last three months, 13 analysts have evaluated Hims & Hers Health HIMS, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table ...

While there's still plenty of work to be done, Hims is one of many such companies that's helping to expand healthcare options, by opening the conversation around men's health, in particular.

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. The treatments will each cost $ ...

Hims & Hers Health (HIMS) has emerged as a disruptive force in telehealth, leveraging technology and personalization to address highly-personal health conditions while achieving scalable ...